Synergistic effects of acarbose and an Oroxylum indicum seed extract in streptozotocin and high-fat-diet induced prediabetic mice

Biomedicine and Pharmacotherapy

Volumn 87, Issue , 2017, Pages 160-170

  Sun, Wenlong ^a   Sang, Yuanbin ^a   Zhang, Bowei ^a   Yu, Xiaoxia ^a   Xu, Qinmin ^a   Xiu, Zhilong ^a   Dong, Yuesheng ^a  

^a DALIAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Acarbose; Anti prediabetes; Mechanism; OISE; Synergistic

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; OROXYLUM INDICUM SEED EXTRACT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLANT EXTRACT; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEK293 CELL LINE; HEPG2 CELL LINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMPAIRED GLUCOSE TOLERANCE; LIPID DIET; LIPID METABOLISM; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OROXYLUM; OXIDATIVE STRESS; PLANT SEED; PRIORITY JOURNAL; WESTERN BLOTTING; ADVERSE EFFECTS; ANIMAL; BARK; BIGNONIACEAE; DIABETES MELLITUS, EXPERIMENTAL; HEP-G2 CELL LINE; ISOLATION AND PURIFICATION; MALE; METABOLISM; PREDIABETIC STATE;

ACARBOSE; ANIMALS; BIGNONIACEAE; DIABETES MELLITUS, EXPERIMENTAL; DIET, HIGH-FAT; DRUG SYNERGISM; HEK293 CELLS; HEP G2 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MICE; PLANT BARK; PLANT EXTRACTS; PREDIABETIC STATE; SEEDS; STREPTOZOCIN;

EID: 85007605400     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.12.096     Document Type: Article

References (29)

1. [1] Wang, J.S., Lin, S.D., Lee, W.J., Su, S.L., Lee, I.T., Tu, S.T., Tseng, Y.H., Lin, S.Y., Sheu, W.H., Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week randomized, open-label, parallel-group comparison. Clin. Ther. 33 (2011), 1932–1942.
2. [2] Holman, R.R., Bethel, M.A., Chan, J.C., Chiasson, J.L., Doran, Z., Ge, J., Gerstein, H., Huo, Y., McMurray, J.J., Ryden, L., Liyanage, W., Schroder, S., Tendera, M., Theodorakis, M.J., Tuomilehto, J., Yang, W., Hu, D., Pan, C., A.C.E.S. group rationale for and design of the acarbose cardiovascular evaluation (ACE) trial. Am. Heart J. 168 (2014), 23–29 e22.
3. [3] Enç, F.Y., İmeryüz, N., Akin, L., Turoğlu, T., Dede, F., Haklar, G., Tekeşi̇n, N.l., Beki̇roğlu, N., Yeğen, B., Rehfeld, J.F., Holst, J.J., Ulusoy, N.s.B., Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release. Am. J. Physiol. 281 (2001), 752–763.
4. [4] Chiasson, J.L., Josse, R.G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., S.-N.T.R. Group, Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia 47 (2004), 969–975.
5. [5] Andrade, R.J., Lucena, M., Vega, J.L., Torres, M., Salmeron, F.J., Bellot, V., Garcia-Escano, M.D., Moreno, P., Acarbose-associated hepatotoxicity. Diabetes Care 21 (1998), 2029–2030.
6. [6] Akkarachiyasit, S., Charoenlertkul, P., Yibchok-Anun, S., Adisakwattana, S., Inhibitory activities of cyanidin and its glycosides and synergistic effect with acarbose against intestinal alpha-glucosidase and pancreatic alpha-amylase. Int. J. Mol. Sci. 11 (2010), 3387–3396.
7. [7] Satoh, T., Igarashi, M., Yamada, S., Takahashi, N., Watanabe, K., Inhibitory effect of black tea and its combination with acarbose on small intestinal alpha-glucosidase activity. J. Ethnopharmacol. 161 (2015), 147–155.
8. [8] Singh, J., Kakkar, P., Modulation of liver function antioxidant responses, insulin resistance and glucose transport by Oroxylum indicum stem bark in STZ induced diabetic rats. Food Chem. Toxicol. 62 (2013), 722–731.
9. [9] Dinda, B., SilSarma, I., Dinda, M., Rudrapaul, P., Oroxylum indicum (L.) Kurz, an important Asian traditional medicine: from traditional uses to scientific data for its commercial exploitation. J. Ethnopharmacol. 161 (2015), 255–278.
10. [10] Re, R., Pellegrini, N., Proteggente, A., Pannala, A., Yang, M., Rice-Evans, C., Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radical Biol. Med. 26 (1999), 1231–1237.
11. [11] Yoon, M.J., Lee, G.Y., Chung, J.J., Ahn, Y.H., Hong, S.H., Kim, J.B., Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes 55 (2006), 2562–2570.
12. [12] Tong, J.J., Chen, G.H., Wang, F., Li, X.W., Cao, L., Sui, X., Tao, F., Yan, W.W., Wei, Z.J., Chronic acarbose treatment alleviates age-related behavioral and biochemical changes in SAMP8 mice. Behav. Brain. Res. 284 (2015), 138–152.
13. [13] Tabák, A.G., Herder, C., Rathmann, W., Brunner, E.J., Kivimäki, M., Prediabetes: a high-risk state for diabetes development. Lancet 379 (2012), 2279–2290.
14. [14] Wang, K., Cao, P., Shui, W., Yang, Q., Tang, Z., Zhang, Y., Angelica sinensis polysaccharide regulates glucose and lipid metabolism disorder in prediabetic and streptozotocin-induced diabetic mice through the elevation of glycogen levels and reduction of inflammatory factors. Food Funct. 6 (2015), 902–909.
15. [15] Ramos-Rodriguez, J.J., Molina-Gil, S., Ortiz-Barajas, O., Jimenez-Palomares, M., Perdomo, G., Cozar-Castellano, I., Lechuga-Sancho, A.M., Garcia-Alloza, M., Central proliferation and neurogenesis is impaired in type 2 diabetes and prediabetes animal models. PLoS One, 9, 2014, e89229.
16. [16] Andrade, J., Conde, M., Sobrino, F., Bedoya, F.J., Activation of peritoneal macrophages during the prediabetic phase in low-dose streptozotocin-treated mice. FEBS Lett. 327 (1993), 32–34.
17. [17] Ito, M., The production of mouse model of slowly progressive diabetes mellitus and the preventive EŠect of low molecular weight chitosan on the progression of the diabetes mellitus. Pharm. Soc. Japan 133 (2013), 773–782.
18. [18] Ceriello, A., Postprandial hyperglycaemia and diabetes complications: is it time to treat?. Diabetes 54 (2005), 1–7.
19. [19] Wascher, T.C., Schmoelzer, I., Wiegratz, A., Stuehlinger, M., Mueller-Wieland, D., Kotzka, J., Enderle, M., Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. Eur. J. Clin. Invest. 35 (2005), 551–557.
20. [20] Baynes, J.W., Role of oxidative stress in development of complications in diabetes. Diabetes 40 (1991), 405–412.
21. [21] Singh, P., Singh, R.L., Kakkar, P., Antioxidant, DNA damage protective and hepatoprotective activities of amorphophallus campanulatus. Int. J. Pharm. Pharm. Sci. 8 (2016), 330–338.
22. [22] Kumari, A., Kakkar, P., Lupeol protects against acetaminophen-induced oxidative stress and cell death in rat primary hepatocytes. Food Chem. Toxicol. 50 (2012), 1781–1789.
23. [23] Bhatia, S., Shukla, R., Venkata Madhu, S., Kaur Gambhir, J., Madhava Prabhu, K., Antioxidant status, lipid peroxidation and nitric oxide end products in patients of type 2 diabetes mellitus with nephropathy. Clin. Biochem. 36 (2003), 557–562.
24. [24] Kim, H.I., Ahn, Y.H., Role of peroxisome Proliferator–activated receptor-γin the glucose-sensing apparatus of liver and β-cells. Diabetes 53 (2004), S61–S65.
25. [25] Feng, X., Qin, H., Shi, Q., Zhang, Y., Zhou, F., Wu, H., Ding, S., Niu, Z., Lu, Y., Shen, P., Chrysin attenuates inflammation by regulating M1/M2 status via activating PPARgamma. Biochem. Pharmacol. 89 (2014), 503–514.
26. [26] DeFronzo, R.A., Tripathy, D., Schwenke, D.C., Banerji, M., Bray, G.A., Buchanan, T.A., Clement, S.C., Henry, R.R., Hodis, H.N., Kitabchi, A.E., Mack, W.J., Mudaliar, S., Ratner, R.E., Williams, K., Stentz, F.B., Musi, N., Reaven, P.D., Pioglitazone for diabetes prevention in impaired glucose tolerance. N. Engl. J. Med., 364, 2011.
27. [27] The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006), 1096–1105.
28. [28] Liang, Y., Tsai, S., Tsai, D., LinShiau, S., Lin, J., Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of peroxisome proliferator-activated receptor-gama by favonoids in mouse macrophages. FEBS Lett. 496 (2001), 12–18.
29. [29] Rehman, M.U., Tahir, M., Khan, A.Q., Khan, R., Lateef, A., Oday, O.H., Qamar, W., Ali, F., Sultana, S., Chrysin suppresses renal carcinogenesis via amelioration of hyperproliferation, oxidative stress and inflammation: plausible role of NF-kappaB. Toxicol. Lett. 216 (2013), 146–158.